Redeye: Xbrane Biopharma Q4 2024 - Eventful times
Redeye provides an updated view on Xbrane following its year-end report, which showed continued growth in end-customer sales and signs of improving financials. However, increasing uncertainty in the ranibizumab market leads us to lower our fair value range.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/